Indoco Remedies P/E Ratio
Indoco Remedies P/E ratio. Indoco Remedies (INDOCO) P/E ratio is not applicable — EPS (TTM) ₹-10.70, 1 consecutive loss quarter. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Consecutive Loss Quarters: 1
Current EPS: ₹-10.70
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -2.57 | -24 | Loss |
| Jun 2026 | 7.09 | 65 | Profit |
| Sept 2025 | -1.00 | -9 | Loss |
| Mar 2025 | -4.48 | -41 | Loss |
| Jun 2025 | -3.94 | -36 | Loss |
| Dec 2025 | -3.20 | -30 | Loss |
| Sept 2024 | -1.09 | -10 | Loss |
| Mar 2024 | 2.39 | 22 | Profit |
Healthcare Peers with Valid P/E Ratios — INDOCO Comparison
Healthcare sector average P/E 52.77, median 32.41 — INDOCO excluded (negative EPS).
Sector Average PE
52.77
Sector Median PE
32.41
Lowest PE
2.04
Profitable Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see INDOCO stock price BSE.
- Examine Indoco Remedies quarterly earnings for recent quarterly revenue, profit and EPS trends.
- Also explore INDOCO price movement history to track price trends across different timeframes.